BCG failure is much less common than previously thought in non-muscle invasive bladder cancer, so is adding a checkpoint ...
The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback